Patients with glaucoma treated with iDose TR experienced sustained IOP reductions, according to a press release from ...

Stand-alone canaloplasty and trabeculotomy with the Omni surgical system showed positive real-world outcomes in reducing IOP ...

Analysts have recently evaluated Sight Sciences and provided 12-month price targets. The average target is $4.72, accompanied ...

Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well ...

Corporation announced several positive clinical updates for its iDose sustained-release procedural pharmaceutical platform, ...

NYSE:GKOS) Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform ...

Glaucoma is a leading cause of preventable blindness, affecting over 3 million Americans. Screening and early detection are critical to preserving vision from ...

More than 3 million people in the U.S. are estimated to be living with glaucoma. By 2030, that number is expected to increase ...

The month of January has been designated National Glaucoma Awareness Month. Glaucoma is a disease that causes damage to the ...

Glaucoma refers to a group of eye conditions that can lead to vision loss and blindness by damaging the optic nerve at the ...

The rates at which ganglion cell-inner plexiform layer (GCIPL) and retinal nerve fiber layer (RNFL) thin in the eyes was ...

Sight Sciences (SGHT) announced the publication of a landmark 36-month analysis evaluating the long-term effectiveness of the OMNI Surgical ...